Shalby consolidated PAT up 8% YoY to ₹7.9 Cr as Medtech losses widen further
PAT +8.35% YoY · revenue +9.72% · margins compressing
₹313.17 Cr
+9.72% YoY
₹7.89 Cr
+8.35% YoY
2.48%
0pp YoY
₹0.73
Shalby's consolidated revenue came in at ₹313.17 Cr (+9.7% YoY, -5.5% QoQ) and consolidated PAT at ₹7.89 Cr (+8.4% YoY, -24.9% QoQ) for Q2 FY27. No quarter-specific street estimate for Q2 FY27 could be located (trackers show only full-year FY27 consensus — EPS ₹4.20, +30% — with a near-unanimous Buy rating), so vs-street is unknown rather than graded.
Q2 FY-2027 vs prior quarters
NPM was essentially flat YoY at 2.52% (vs 2.51%) but down sequentially from 3.10% in Q1 FY27; OPM came in at 13.22%, down from 14.58% a year ago though up from Q1's 12.56%. The Healthcare Services segment, the core of the business, grew PBT 9.8% YoY to ₹28.11 Cr on 12.1% revenue growth to ₹283.21 Cr — consistent with management's push toward the 20% hospital EBITDA margin target it set out for FY27 in the August 2026 concall, though no EBITDA breakout is disclosed to confirm the exact trajectory. Working against this, the Manufacturing & Trading of Implants (Medtech) segment's loss widened 78% YoY to ₹11.64 Cr on an 8.8% revenue decline to ₹29.97 Cr — the opposite of management's guidance that regulatory changes would bring Medtech to double-digit EBITDA margins within 6-9 months. The segment's deterioration coincides with Shalby Medtech CEO Deepak Anand's resignation on August 18, 2026, with no replacement named in this filing.
The stock went into the print at ₹122.13, down 8.6% over the past month of trading.
Hospital EBITDA margin targeting upward to 20% for FY27. MedTech targeting double-digit EBITDA margins post-regulatory changes (6-9 months). ROCE expansion to 11-13% industry standard within 1-2 years via capex ROI and minimal further capex planned.
— This quarter: missed
No management press release accompanies this result, so there is no company framing to reconcile against the numbers. Standalone PAT of ₹23.50 Cr (EPS ₹2.19) is well above consolidated PAT of ₹7.89 Cr (EPS ₹0.73); the gap is entirely subsidiary-level losses, chiefly Medtech, consolidating down group profit. Both statements carry no exceptional items this quarter or a year ago, so YoY growth is on a clean base. Separately, the board approved appointing Shanay Vikram Shah and Tushar Shah as Whole-Time/Executive directors, subject to a shareholder postal ballot due December 5, 2026 — a governance move unconnected to this quarter's operating print.
W1
Medtech segment EBITDA margin trajectory — management guided double-digit margins within 6-9 months of regulatory changes (Aug 2026 concall); segment loss was ₹11.64 Cr this quarter, widened from ₹6.52 Cr YoY
W2
Hospital EBITDA margin progress toward management's 20% FY27 target — Healthcare segment PBT margin was ~9.9% this quarter
W3
Jabalpur hospital fire disruption (registration suspended Oct 14, 2026; full operations resumed Oct 28, 2026) falls in Q3 FY27 — watch for revenue/margin impact in the next print
Source is in ₹ Million, converted to Crore (÷10). No exceptional items in current or year-ago quarter (both periods). Consolidated 'Profit for the period' (₹7.886 Cr, before NCI split) is used as netProfit, consistent with DB convention — this exact figure reconciles with the prior-quarter (₹10.496 Cr) and year-ago (₹7.278 Cr) DB values pulled from this same statement's columns. Tax figure derived as current tax + adjustment for earlier years + deferred tax (MAT credit nil this quarter).
9% growth masks hospital margin squeeze; Gurgaon breakout doesn't offset core pressure
Revenue is on track for double-digit FY27, but the quarter exposed deep cracks: hospital EBITDA margin fell 130 bps YoY to 18.2%, missing the 20% target. Worse, PAT collapsed 24.9% QoQ while revenue fell only 5.4% — a leverage inversion that management never explained.
-5.4%
Sequential softness
-24.9%
4x the revenue decline
18.2%
vs 19.5% prior year, vs 20% target
On the headline, Shalby delivered 9.7% YoY revenue growth and 8.3% PAT growth — steady enough. But read the quarter sequentially and the picture inverts: revenue fell 5.4% QoQ, and profit crashed 24.9% QoQ. That 4x leverage collapse — where revenue barely declined but profit halved — signals either one-time Q2 costs or a procedure mix shift. Management didn't explain it, only deferred margin benefits to Q4.
The deeper issue is the hospital business. Stand-alone EBITDA margin compressed to 18.2% from 19.5% a year ago — a 130 bps erosion — while management is still publicly targeting 20% for FY27. That gap is no longer a rounding error. With occupancy at 52% and ARPOB growth only 4.3% YoY, the core franchise is not earning to its own guidance.
What held up on the call, and what didn't
Hospital business remains core, profitable activity with significant headroom
OverstatedStand-alone margin 18.2% vs 19.5% YoY (−130 bps); target 20% now at risk
Gurgaon unit delivering strong growth trajectory, approaching breakeven
SupportedRevenue ~₹30 Cr (+50% YoY); EBITDA positive 2 consecutive quarters; occupancy 55%; ARPOB ₹96k (+18% YoY)
ROCE expansion progressing toward 11-13% industry standard
ContradictedAnnualized ROCE 9.4%; below guidance, no recovery timeline
MedTech targeting double-digit EBITDA margins post-regulatory changes
OverstatedEBITDA positive 5 consecutive quarters; no margin % disclosed; path to double-digit margins unquantified
Margin support expected from operational efficiencies and new supply chain model
PartialEBITDA margin flat YoY at 14.6% vs 15.9%; hospital margin compressed despite efficiency initiatives
What changed vs. the prior quarter
Gurgaon unit accelerating upward
Revenue ~₹30 Cr (+50% YoY); EBITDA positive for 2 consecutive quarters; occupancy 55%; targeting PBT breakeven by Q3/Q4 FY27
Hospital margin pressured downward
Stand-alone margin 18.2% vs 19.5% YoY (−130 bps); vs 20% guidance target, now at risk. Cost pressures cited but no specific recovery timeline
ROCE guidance miss confirmed
Annualized ROCE 9.4% vs prior 11-13% target. Capex ROI deferred; no improvement timeline disclosed
MedTech profitability inflection
5th consecutive quarter EBITDA positive; consolidated Q2 EBITDA ₹3.6 Cr vs ₹1.6 Cr Q1. Still no path to double-digit margins quantified
The bull-bear ledger
Gurgaon 50% growth; EBITDA positive 2 consecutive quarters — genuine execution on the new platform
MedTech EBITDA positive 5 consecutive quarters; new supply chain reducing COGS 30-40%; prior ₹165 Cr loss turning into margin contribution
Net debt declining (₹458 Cr vs ₹554 Cr YoY); gearing 0.45x; capex disciplined at ₹10 Cr per half
Occupancy rising to 52% from 48% YoY; specialist network expanding; ALOS improved to 3.58 days; runway for leverage
Hospital margin compressed 130 bps YoY; target of 20% now at risk; no clear path to recovery articulated
PAT -24.9% QoQ while revenue -5.4% QoQ; Q2-specific headwinds never explained; profit volatility higher than implied
ROCE at 9.4% vs 11-13% guidance; capex ROI underperforming or leverage limiting returns; no recovery timeline
MedTech: no quantified path to double-digit margins; management deferred numbers; turnaround narrative still unproven
Strategy ambiguity on hospital vs. MedTech vs. Gurgaon; hospital-only capex allocation not disclosed; analyst pushback deflected
Risks, ranked by holder concern
Hospital margin compression continues; 20% target now at risk
HighCore profit engine losing leverage. Margin fell 130 bps YoY and is tracking below guidance. If compression persists into Q3/Q4, the hospital thesis breaks and normalization of multiples likely.
ROCE below 11-13% guidance with no recovery timeline
HighSignals capex ROI underperforming or debt burden limiting returns. If capex cycles higher without ROI recovery, leverage rises and equity returns compress.
QoQ PAT collapse (-24.9% vs -5.4% revenue) unexplained; structural weakness possible
HighIf Q2 cost pressures repeat, profit power is structurally lower than guided. If one-time, timing matters — but silence on the call raises credibility doubt on near-term visibility.
MedTech: no clear path to double-digit EBITDA margins disclosed
MediumPrior ₹165 Cr loss; EBITDA positive but small (₹3.6 Cr). Management evasion ('unable to give you numbers') on roadmap raises doubt on execution confidence and turnaround credibility.
Gurgaon unit dependency; PBT breakeven by Q3/Q4 FY27 is tight timeline
MediumUnit is only ~10% of hospital revenue; 50% growth is impressive but scale still small. If occupancy growth stalls or costs rise, breakeven gets pushed and capex ROI declines.
Hospital occupancy at 52% still below potential; execution risk if improvement slows
MediumManagement claims '50% revenue upside at full utilization,' but occupancy growth has only +400 bps YoY and momentum is unclear. If occupancy stalls, margin recovery thesis loses its key lever.
NPPPA drug capping effective mid-November 2026; oncology margin risk
LowManagement expects limited impact (medicines bundled in surgeries), but if implementation is stricter or affects implant-related pharma, margins compress unexpectedly.
How the street is positioned
The stock has lost 65% from its all-time high of ₹339.5 and is now trading at ₹118.35, well below all three major simple moving averages (SMA20 ₹123.35, SMA50 ₹135.86, SMA200 ₹155.05). The RSI at 35.9 shows weak momentum. Near the 52-week low of ₹110.61, the stock has recovered 7% off lows but is still deeply beaten. This drawdown prices in either structural profit loss or a permanent de-rating of multiples.
On the ownership side, FII holdings are steady at 4.46% (up 0.1pp from Q1), and promoter is locked in at 74.33%. No material selling pressure from institutions; if anything, the slight FII uptick suggests some accumulation at depressed levels. But the framing remains cautious — no enthusiastic call from any major holder yet.
The paradox is stark: the stock is cheap by absolute valuation (near 52-week low), but the quarter's miss on hospital margin guidance and the unexplained QoQ PAT collapse have shattered execution credibility. The 65% loss from ATH is no longer speculative froth; it's pricing in a permanent earnings reset. This quarter — rather than sparking a relief bounce — reinforced the bear thesis: hospital margins are compressing, not recovering, and management has no clear answer.
The debate
What to watch next
1 · Hospital EBITDA margin stabilizes or improves
Must recover to at least 19%+ in Q3 to restore guidance credibility. Current 18.2% and compressing trend (three quarters down) signals structural pressure, not cyclical. If margin continues lower into Q3, the 20% target is abandoned and re-rating accelerates.
2 · Gurgaon unit achieves PBT breakeven by Q3/Q4 FY27
Management's tight guidance on this timeline will determine execution credibility on the new platform. Occupancy at 55% has room to run; if it slows or costs rise, breakeven slips and capex ROI questions deepen.
3 · MedTech supply chain cost benefits flow through in H2 FY27
Management promised 30-40% COGS reduction and targeted full benefits by Q4. Consolidated EBITDA doubled from Q1 to Q2 (₹1.6 Cr → ₹3.6 Cr), but margins are still small. H2 results will show if the turnaround is real or just seasonal volatility.
Shalby is at an inflection point: the old hospital-only story is compressing (margin, ROCE), but the new multi-platform story (Gurgaon, MedTech) is still too small to carry earnings. This quarter exposed the gap. Gurgaon is genuine progress, but at ₹30 Cr revenue (~10% of hospital base), it cannot yet offset hospital margin erosion.
The single number to track from here is hospital EBITDA margin. At 18.2% and falling, it is below guidance and raising doubt on whether management's efficiency and specialist expansion thesis is real execution or just talk. If margin stabilizes or improves in Q3/Q4, the bull case holds and the stock finds support. If it compresses further, the 65% loss from ATH was only the first leg of re-rating.
Rating: Hold. The debate is unresolved; execution in Q3/Q4 FY27 will decide whether this is a cyclical stumble (opportunity) or a structural reset (risk).
9% growth masked by margin compression; Gurgaon bright spot offsets hospital headwinds
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Hospital EBITDA margin (18.2%) misses 20% target. ROCE (9.4%) below 11-13% guidance. No miss on revenue growth (+9.7% on track).
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Shalby shows genuine progress on Gurgaon scaling and capex discipline (₹10 Cr per half), but near-term margins are compressing (hospital 18.2% vs 19.5%, down from 20% guidance) and PAT fell 24.9% QoQ despite 9.7% YoY revenue growth. ROCE at 9.4% lags 11-13% target. The call mixed confidence on long-term (Gurgaon PBT breakeven Q3/Q4, MedTech now EBITDA positive) with execution headwinds and strategy ambiguity (hospital vs MedTech focus).
₹313.2 Cr
Revenue · +9.7% YoY₹7.9 Cr
Reported PAT · +8.3% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Hospital business remains core, profitable activity with significant headroom
OVERSTATEDStand-alone hospital margin 18.2% vs 19.5% YoY; below 20% guidance; occupancy at 52% vs 48%, still below potential
Gurgaon unit delivering strong growth trajectory and approaching breakeven
METGurgaon revenue ~₹30 Cr vs ₹20 Cr (50% YoY growth), EBITDA positive for 2 consecutive quarters, occupancy 55%, ARPOB ₹96k (+18% YoY)
ROCE expansion progressing toward 11-13% industry standard
MISSAnnualized ROCE now 9.4%, below the 11-13% prior guidance target
MedTech targeting double-digit EBITDA margins post-regulatory changes
OVERSTATEDMedTech EBITDA positive for 5 consecutive quarters but consolidated EBITDA only ₹3.6 Cr; no margin percentage disclosed; still building volumes
Margin support expected from operational efficiencies and new supply chain model
PartialEBITDA margin flat YoY at 14.6% vs 15.9%; hospital margin compressed despite efficiency initiatives cited; benefits deferred to Q4 onwards
Earnings quality
What changed since the last call
Gurgaon unit accelerating
UpgradeRevenue ~₹30 Cr vs ₹20 Cr (50% YoY); EBITDA positive for 2 consecutive quarters; occupancy 55%; ARPOB ₹96k (+18% YoY) vs prior guidance vague on Gurgaon timeline
Hospital margin pressured
DowngradeStand-alone margin 18.2% vs 19.5% YoY (-130 bps), vs prior guidance target of 20%. Cost headwinds cited; no specific recovery timeline
ROCE missed guidance
DowngradeAnnualized ROCE 9.4% vs prior 11-13% target. Capex ROI deferred; prior guidance implied improvement, not stagnation
MedTech status: now EBITDA positive
Upgrade5th consecutive quarter of positive EBITDA; consolidated Q2 ₹3.6 Cr vs ₹1.6 Cr Q1. Still no path to double-digit margins quantified
The Q&A
Analysts pressed hard on hospital business profitability vs implant subsidiary losses (INR165 Cr over 3 years) and strategic focus. Management defended hospital 'core' status and cited turnaround opportunity in implants, but deflected on specific hospital-only capex allocation and forward profitability milestones.
Hospital vs MedTech strategy — Moksh Morbia, Prospero Tree
PartialHospital business is core, profitable, with 50% revenue upside. Implants are strategic diversification; facility acquired at ₹1,100 Cr, costs halved, positioning as long-term opportunity. New supply chain reducing cost 30-40%.
Implant subsidiary losses — Moksh Morbia, Prospero Tree
PartialCost structure was inherited, now optimized. New supply chain and product expansion expected to improve profitability. Management claims 'all fresh capital will be invested in hospitals, 80-90% of new capex.'
NPPPA drug capping impact — Kashish Thakur, Elara Securities
AnsweredNotification expected mid-November. Expect 30% margin from MRP. Internal analysis shows limited impact; already modeled in guidance. Majority of surgeries bundled, medicines not sold separately.
Gurgaon profitability timeline — Moksh Moury; Kashish Thakur, Elara Securities
AnsweredUnit now EBITDA positive for 2 consecutive quarters at H1 level. Occupancy growing, specialties adding yield. Expecting PBT breakeven by Q3/Q4 FY27. ARPOB ₹96k (+18% YoY).
Capex and tax rate FY27 — Kashish Thakur, Elara Securities
AnsweredH1 capex ₹10 Cr, similar in H2. Tax rate fallen to 24% (vs 35% prior year) due to Gurgaon unit losses offset. ETR expected 45-50% with EBITDA improvements; further reduction possible.
FY27 revenue and margin guidance — Kashish Thakur, Elara Securities
PartialDouble-digit growth in topline expected (H1 tracking this). Hospital margin support from new supply chain, efficiency, NPPA benefits, additional specialists. Full-year benefit in Q4; H2 will be stronger than H1 in terms of growth and margins.
MedTech 2-3 year roadmap (EBITDA, debt reduction) — Supraja, Cuz Limited
DodgedUnable to give numbers due to new supply chain and expansion. Expect benefits to accrue gradually over rest of FY27 and beyond. Debt will reduce with EBITDA positive, cash flow improvement. No specific EBITDA margin or debt target quantified.
Expansion plans (Mumbai, others) — Kashish Thakur, Elara Securities
PartialMumbai expansion delayed with trustee approvals pending. Other avenues being evaluated. No update timeline provided. Focus on utilization of existing infrastructure.
FOSO (Franchise of Standalone Orthopedic) strategy — Kashish Thakur, Elara Securities
AnsweredOnly concentrating on profitable FSOSs. Limited operations to profitable FSOSs. Quality KPI focus, not just financial. Selective approach on new FSOSs.
Guidance
Double-digit topline growth for FY27 (from H1 reference: +9.8% delivered)
MediumH1 tracking; H2 expected stronger than H1. No specific FY27 revenue target quantified; implied 10%+ if double-digit claim holds.
Hospital EBITDA margin targeting upward toward 20% for FY27 (prior Q1 guidance)
LowCurrent stand-alone margin 18.2% (vs 19.5% YoY); compression 130 bps. No explicit reaffirmation on 20% target this call; only stated benefits from Q4 onwards. Execution risk evident.
MedTech targeting double-digit EBITDA margins post-regulatory changes (6-9 months from Q1 guidance)
LowCurrently EBITDA positive only; no margin percentage disclosed. Supply chain benefits deferred to H2 FY27 and FY28. No specific margin target quantified.
H1 ₹10 Cr capex; similar level expected in H2 (total ~₹20 Cr for FY27)
HighH1 actual delivered; hospital tech investments (robotics, scanners), MedTech supply chain setup, Gurgaon FSI utilization.
Risks the call surfaced
Execution on margin guidance
HighHospital margin 18.2% vs 20% guidance, down 130 bps YoY. Cost headwinds (staffing, utilities) not yet offset by efficiency gains. Q4 benefits promised but track record of compression in Q2 raises doubt.
ROCE below target
HighAnnualized ROCE 9.4% vs prior guidance of 11-13% expansion target. Capex running at ₹10 Cr per half; if ROI on new beds/tech underperforms, ROCE will remain stuck below guidance.
MedTech profitability path
MediumMedTech acquired in 2021 with ₹165 Cr cumulative loss over 3 years. Now EBITDA positive for 5 consecutive quarters, but no specific margin % disclosed. Management deferred quantified roadmap, citing inability to share numbers.
Hospital occupancy execution
MediumStand-alone occupancy 52% (48% prior), +400 bps YoY. Gurgaon at 55%. Management claims 'some hospitals still operating below potential,' implying utilization risk. 50% revenue upside if fully leveraged, but timing uncertain.
Gurgaon unit dependency
MediumGurgaon contributed 50% revenue growth (₹30 Cr vs ₹20 Cr), but represents ~10% of hospital revenue. Occupancy at 55% and ARPOB growing, but PBT breakeven by Q3/Q4 is a tight timeline if costs rise.
Debt and capex cycle mismatch
MediumNet debt ₹458 Cr (gearing 0.45x); capex ₹10 Cr per half (~₹20 Cr annual). If capex ROI lags and occupancy doesn't improve, debt-to-EBITDA could deteriorate. Management claims confidence in debt reduction but specific milestones absent.
NPPPA drug capping regulatory risk
LowNPPPA capping 180 molecules (oncology focus). Management expects 30% MRP margin; claims limited impact since medicines bundled in surgeries. But if implementation is harsher or affects implant-related pharma, margins could compress.
Management
Score 7/10. Candid on challenges (margin compression, occupancy 'below potential,' cost headwinds). Evasive on MedTech profitability roadmap and long-term strategic focus (hospital vs implants); deferred numbers on both. Clear on capex and tax rate guidance. Mixed track record. Hospital EBITDA margin missed 20% guidance (18.2% current). ROCE below 11-13% guidance at 9.4%. Gurgaon tracking well (50% growth, EBITDA positive). Revenue growth on track (+9.7% YoY, on pace for double-digit FY27). Cost control improving (inventory down 20%, ALOS improved).
1 · Q3/Q4 FY27
Gurgaon (Shalby International) targeting PBT breakeven; EBITDA benefits flow through
2 · Q4 FY27
New MedTech supply chain cost reductions fully effective; manufacturing yield improvements realized
3 · H2 FY27
Additional specialist doctors added across network to drive multi-specialty growth and occupancy utilization
The call mixed confidence on long-term (Gurgaon PBT breakeven Q3/Q4, MedTech now EBITDA positive) with execution headwinds and strategy ambiguity (hospital vs MedTech focus).